## **IN THE CLAIMS**

Please replace Claims 3 and 5 with the following amended claims:

E

an amino acid sequence consisting essentially of SEQ ID NO: 6, wherein the polypeptide is conjugated with at least one binding agent selected from the group consisting of a monoclonal antibody, single chain antibody, phage-display evolved antibody, and in-vitro evolved antibody.

(Twice Amended) A composition for treating prostate cancer, comprising an isolated polypeptide comprising an amino acid sequence consisting essentially of SEQ ID NO: 6, conjugated with a binding agent capable of inhibiting binding of the polypeptide to its receptor, thereby inhibiting an ability of the polypeptide to induce prostate cancer cell growth, the binding agent selected from the group consisting of monoclonal antibody, partially or fully humanized monoclonal antibody, polyclonal antibody, antibody selected by phage display selection, single chain antibody, and in-vitro evolved antibody.

Please cancel Claims 2, 6, 8-10, and 22-29 without prejudice or disclaimer.